AI Article Synopsis
- Brown tumours, typically linked to primary hyperparathyroidism, are rarely caused by vitamin D deficiency; this case involves a 50-year-old woman with a low dietary intake of vitamin D.
- The patient developed Brown tumours in the tibia and second metacarpal bone due to vitamin D deficiency and secondary hyperparathyroidism, exacerbated by limited sunlight exposure.
- Treatment with vitamin D3 and calcium supplements led to improvement, marking this as a rare case of Brown tumours specifically related to vitamin D deficiency.
Article Abstract
Brown tumours caused by vitamin D deficiency are rare. Most cases are caused by primary hyperparathyroidism, and are rarely caused by secondary hyperparathyroidism in cases of renal failure. We present a case of Brown tumours of the tibia and second metacarpal bone in a 50-year-old woman who had a low dietary intake of vitamin D and had worn a veil for most of her adult life. The Brown tumours were caused by vitamin D deficiency and secondary hyperparathyroidism. The patient improved on treatment with vitamin D3 and calcium supplements. This is a rare case and the first, to our knowledge, with a Brown tumour of the tibia caused by vitamin D deficiency due to decreased dietary intake and decreased exposure to sunlight. The course of treatment and investigations of the patient are described.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4533646 | PMC |
| http://dx.doi.org/10.1136/bcr-2014-207722 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A phase II trial of larotrectinib in tumors with NTRK fusions or extremes of NTRK mRNA overexpression identified by comprehensive genomic profiling.
Oncologist
December 2024
The Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, NSW 2010, Australia.
Background: TRK-inhibitors have demonstrated efficacy across several cancers with NTRK fusions. Their activity in cancers with NTRK overexpression remains unclear.
Methods: This trial enrolled patients with advanced cancers harboring NTRK fusions or extreme mRNA overexpression, defined as NTRK1/2/3 expression by RNA profiling >5 SDs for a given cancer type.
Brown tumors in primary hyperparathyroidism initially interpreted as bone metastases and multiple gigantocelular tumors: case report.
EJNMMI Rep
December 2024
Department of Oncology and Nuclear Medicine, University Hospital Centre Sestre Milosrdnice, Zagreb, Croatia.
Brown tumors or osteitis fibrosa cystica are a rare bone metabolism disorder that may mimic cancer metastasis. It represents a late manifestation of prolonged and mostly unrecognized hyperparathyroidism. In this case report we present a 44-year-old female patient with multiple lesions detected on bone scintigraphy and F- FDG-PET/CT, initially interpreted as a bone metastatic disease, rather than multiple gigantocellular bone tumors.
View Article and Find Full Text PDFLong term follow-up of women treated for screen detected atypical ductal hyperplasia or lobular neoplasia in a large UK screening centre.
BJC Rep
December 2024
Manchester University NHS Foundation Trust, Wythenshawe Hospital, Southmoor Road, Manchester, UK.
Background: Atypical ductal hyperplasia (ADH) and lobular neoplasia (LN) increase subsequent breast cancer (BC) risk. However, optimal surveillance and risk reduction regimes remain uncertain. We report management and outcomes of women with ADH and LN to provide data on potential screening/prevention strategies.
View Article and Find Full Text PDFPDX models for functional precision oncology and discovery science.
Nat Rev Cancer
December 2024
Department of Oncological Sciences, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, USA.
Precision oncology relies on detailed molecular analysis of how diverse tumours respond to various therapies, with the aim to optimize treatment outcomes for individual patients. Patient-derived xenograft (PDX) models have been key to preclinical validation of precision oncology approaches, enabling the analysis of each tumour's unique genomic landscape and testing therapies that are predicted to be effective based on specific mutations, gene expression patterns or signalling abnormalities. To extend these standard precision oncology approaches, the field has strived to complement the otherwise static and often descriptive measurements with functional assays, termed functional precision oncology (FPO).
View Article and Find Full Text PDFMass-forming intrahepatic cholangiocarcinoma: treatment outcomes after curative-intent resection in an Australian tertiary referral hospital.
ANZ J Surg
December 2024
Department of Upper Gastrointestinal Surgery, Royal North Shore Hospital, Sydney, New South Wales, Australia.
Background: Mass-forming intrahepatic cholangiocarcinoma (MF-ICC) is the second most common primary liver cancer and liver resection offers the best chance of possible cure. This study aimed to assess treatment outcomes and prognostic factors for long-term survival in patients who underwent curative-intent liver resection.
Methods: A retrospective analysis was conducted on prospectively collected data from patients with MF-ICC managed at the Royal North Shore/North Shore Private Hospital from January 1998 to October 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!